Exploring the MASLD CKD Socioeconomic Link

By Crystal Lubbe

April 10, 2025

How are MASLD and CKD interconnected, and what role do geography and socioeconomic factors play? A recently published article examines the relationship between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Chronic Kidney Disease (CKD) from a socioeconomic perspective. A geographical correlation exists between MASLD and CKD incidence, influenced by factors like the Socio-Demographic Index (SDI).

Key Insights in the MASLD CKD socioeconomic link

The study reveals a strong association between MASLD incidence and CKD, particularly in low SDI countries.

  • Geographical Correlation: MASLD and CKD show similar regional distributions. High incidence rates occur in North Africa and the Middle East.
  • Socioeconomic Influence: The association between MASLD and CKD varies by SDI status. Significant correlations are found in low SDI countries but not in high SDI countries.
  • Risk Factors: Metabolic risk factors like high blood pressure, fasting plasma glucose, and BMI contribute to CKD incidence variance.

Background Context

Metabolic dysfunction-associated fatty liver disease (MAFLD) and MASLD strongly link, both increasing CKD risk through shared factors such as type 2 diabetes, hypertension, obesity, and dyslipidemia. As CKD’s global burden rises, it is expected to become a leading cause of death by 2040. Socioeconomic factors significantly influence disease distribution and management, with disparities often emerging in low-income settings. For more information, refer to the source here.

Implications

The findings have significant implications for health economics and outcomes research:

  • Targeted Interventions: Public health strategies should address socioeconomic contexts to mitigate MASLD and CKD burden effectively.
  • Economic Burden: Addressing the MASLD CKD socioeconomic link could reduce healthcare costs by preventing complications and improving outcomes.
  • Equitable Health Outcomes: Understanding socioeconomic factors can help design policies promoting equitable healthcare access and reducing disparities.
Reference url

Recent Posts

Strategic Avalere Health Appointments Enhance Leadership in Navigating US Healthcare Policy Changes

By João L. Carapinha

December 17, 2025

Avalere Health strengthened its appointments, with Matt Kazan returning as Senior Vice President of Policy, where he previously served as a former top advisor on the US Senate Committee on Finance, and he will now lead the policy team amid changes like the Inflation Reduction Act. Laura Housman, ...
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
BIC/LEN HIV Regimen Delivers Non-Inferior Results in ARTISTRY-2 Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial, demonstrating that the investigational BIC LEN HIV regimen
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals

By HEOR Staff Writer

December 16, 2025

The CHMP meeting highlights from December 2025 reveal major advancements in drug approvals. What were the key outcomes of the EMA's Committee for Medicinal Products for Human Use session held December 8-11? The committee recommended seven new medicines for approval. These target critical areas li...